Inventor · disambiguated record

Jonathan Basil Fitzgerald

Also filed as: FITZGERALD JONATHAN B · FITZGERALD JONATHAN BASIL

19 granted patents·28 pending applications·156 citations·filing 2009–2025

95Inventor score

Technology areasA61K A61P C07K C12Q G01N

Files withIPSEN BIOPHARM LTD23 MERRIMACK PHARMACEUTICALS INC20 SCHOEBERL BIRGIT2 BAUM JASON1 MERRIRNACK PHARMACEUTICALS INC1

Top patents by PatentIndex Score

47 records

0197US9717724B2Methods for treating pancreatic cancer using combination therapiesIPSEN BIOPHARM LTD·Filed 2016·Granted Aug 1, 2017·14 cites·24 claims
0296US10980795B2Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecanIPSEN BIOPHARM LTD·Filed 2018·Granted Apr 20, 2021·8 cites·15 claims
0396US9492442B2Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecanMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Nov 15, 2016·19 cites·30 claims
0495US11844795B2Combination therapy for cancer treatmentIPSEN BIOPHARM LTD·Filed 2022·Granted Dec 19, 2023·2 cites·15 claims
0595US9339497B2Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecanMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted May 17, 2016·17 cites·27 claims
0694US9364473B2Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecanMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Jun 14, 2016·12 cites·29 claims
0793US11369597B2Methods for treating pancreatic cancer using combination therapiesIPSEN BIOPHARM LTD·Filed 2018·Granted Jun 28, 2022·4 cites·13 claims
0893US10478428B2Combination therapy for cancer treatmentIPSEN BIOPHARM LTD·Filed 2017·Granted Nov 19, 2019·11 cites·17 claims
0992US9895365B2Combination therapy for cancer treatmentIPSEN BIOPHARM LTD·Filed 2016·Granted Feb 20, 2018·10 cites·20 claims
1092US9452162B2Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecanMERRIMACK PHARMACEUTICALS INC·Filed 2013·Granted Sep 27, 2016·12 cites·35 claims
1191US8476409B2Bispecific anti-IGF-1R and anti-ErbB3 antibodiesBAUM JASON·Filed 2012·Granted Jul 2, 2013·22 cites·15 claims
1290US11344552B2Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatinIPSEN BIOPHARM LTD·Filed 2017·Granted May 31, 2022·4 cites·15 claims
1389US2024226090A1Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal IrinotecanIPSEN BIOPHARM LTD·Filed 2024·Application pending·0 cites
1488US2024342162A1Methods For Treating Pancreatic Cancer Using Combination TherapiesIPSEN BIOPHARM LTD·Filed 2024·Application pending·0 cites
1587US11071726B2Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin)IPSEN BIOPHARM LTD·Filed 2017·Granted Jul 27, 2021·6 cites·21 claims
1687US8623592B2Methods and systems for predicting response of cells to a therapeutic agentSCHOEBERL BIRGIT·Filed 2009·Granted Jan 7, 2014·9 cites·11 claims
1786US11318131B2Nanoliposomal irinotecan for use in treating small cell lung cancerIPSEN BIOPHARM LTD·Filed 2017·Granted May 3, 2022·3 cites·30 claims
1883US2024358706A1Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and OxaliplatinIPSEN BIOPHARM LTD·Filed 2024·Application pending·0 cites
1982US12364691B2Methods for treating pancreatic cancer using combination therapiesIPSEN BIOPHARM LTD·Filed 2022·Granted Jul 22, 2025·0 cites·5 claims
2079US9556274B2Monospecific and bispecific anti-IGF-1R and anti-ERBB3 antibodiesMERRIMACK PHARMACEUTICALS INC·Filed 2013·Granted Jan 31, 2017·2 cites·10 claims
2177US2022096458A1Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal IrinotecanIPSEN BIOPHARM LTD·Filed 2021·Application pending·0 cites
2277US2025381191A1Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and OxaliplatinIPSEN BIOPHARM LTD·Filed 2025·Application pending·0 cites
2375US2023062425A1Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and OxaliplatinIPSEN BIOPHARM LTD·Filed 2022·Application pending·0 cites
2473US9527914B2Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodiesMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Dec 27, 2016·1 cites·6 claims
2567US2014127238A1Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted responseMERRIMACK PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
2666US2017368056A1Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecanIPSEN BIOPHARM LTD·Filed 2017·Application pending·0 cites
2766US2017049768A1Methods for treating pancreatic cancer using combination therapiesMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
2864US2017065578A1Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecanMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
2963US2018008591A1Methods for Treating Pancreatic Cancer Using Combination TherapiesIPSEN BIOPHARM LTD·Filed 2017·Application pending·0 cites
3063US2020360367A1Treatment of Breast Cancer with Liposomal IrinotecanIPSEN BIOPHARM LTD·Filed 2019·Application pending·0 cites
3163US2020268742A1Combination Therapy for Cancer TreatmentIPSEN BIOPHARM LTD·Filed 2019·Application pending·0 cites
3262US2016228428A1Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecanMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
3361US9938346B2Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodiesMERRIMACK PHARMACEUTICALS INC·Filed 2016·Granted Apr 10, 2018·0 cites·24 claims
3459US2019142822A1Treatment of Breast Cancer with Liposomal IrinotecanIPSEN BIOPHARM LTD·Filed 2018·Application pending·0 cites
3558US2017307631A1Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted responseMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
3658US2023000858A1Nanoliposomal Irinotecan for Use in Treating Small Cell Lung CancerIPSEN BIOPHARM LTD·Filed 2022·Application pending·0 cites
3757US2011027291A1Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted responseMERRIMACK PHARMACEUTICALS INC·Filed 2010·Application pending·0 cites
3855US2014170075A1Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agentsMERRIRNACK PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
3954US2017049775A1Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and OxaliplatinMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
4054US2017210809A1Bispecific binding agents targeting the igf-1r and erbb3 pathways and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
4153US2017340656A1Non-Invasive Imaging Methods for Patient Selection for Treatment with Nanoparticulate Therapeutic AgentsMERRIMACK PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
4252US2017151226A1Treatment of Breast Cancer with Liposomal IrinotecanMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
4350US2012244163A1Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereofSCHOEBERL BIRGIT·Filed 2012·Application pending·0 cites
4447US2011125468A1Using response surfaces for screening inhibitor combinations and digital processing methodsMERRIMACK PHARMACEUTICALS INC·Filed 2010·Application pending·0 cites
4544US2017202840A1Treatment of pancreatic cancer with liposomal irinotecanMERRIMACK PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
4642US2017333421A1Population Pharmacokinetics of Liposomal IrinotecanIPSEN BIOPHARM LTD·Filed 2017·Application pending·0 cites
4740US2016346272A1Treatment of breast cancer with liposomal irinotecanMERRIMACK PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites

Join the waitlist — get patent alerts

Get an alert when Jonathan Basil Fitzgerald files or is granted a new patent.

We store only your email — no account needed. See our privacy policy.

Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →